Penetration testing for BCIs, neurostimulators, DBS, and closed-loop neuromodulation. Implant RF, programmer trust, and patient-app exposure tested.
Last reviewed March 2026 · Reviewed against the FDA Feb 3, 2026 final premarket cybersecurity guidance.
NeuroTechnology devices - BCIs, DBS systems, spinal cord stimulators, closed-loop neuromodulation - pair the regulatory weight of a Class III implant with the consumer-app exposure of a wearable. A compromise of stimulation parameters can affect motor control, mood, or cognition directly. Pen testing for this segment is necessarily a system-of-systems test: implant ↔ clinician programmer, implant ↔ patient remote, programmer ↔ cloud, and the closed-loop path inside the implant itself.
We analyze the wireless link to the implant - typically MICS, BLE, or a proprietary RF profile - for pairing strength, session uniqueness, and whether stimulation-parameter writes are gated by an additional clinician-presence factor. We exercise the clinician programmer (often a hardened tablet) for credential storage, session timeout, and whether a stolen programmer is meaningfully different from a stolen consumer phone (it usually isn't, by default). On the patient side we test the consumer companion app the way an attacker would: rooted device, instrumented runtime, MITM with pinned certs bypassed - looking for whether the implant collapses to trusting the app's view of the world. For closed-loop systems we audit the sensing-to-stimulation control integrity: can a spoofed neural signal drive the actuator, and what's the fail-safe if the sense path is suppressed? Reports are framed as risk-control evidence the regulatory team can take into a Q-Sub conversation.
The neurotech / bci system, from the outermost cloud and clinician surfaces down to the device itself. Highlighted layers are exercised by this medical device penetration testing.
Layers shown outermost (top) to innermost (bottom). Dashed rows are part of the surrounding system but out of scope for this view.
Four phases, fixed fee, scoped to neurotech / bci architecture from kickoff onward.
Architecture review, attack-surface walkthrough, and threat-model alignment with your team. Written scope in 24 hours.
Every STRIDE entry in your threat model is matched to a planned test case so reviewers see one-to-one coverage.
Device, cloud, mobile, BLE/RF, and OTA channels exercised in parallel by senior engineers - not a single web-app scan.
eSTAR-format report with findings, CVSS, remediation, and retests until every finding with uncontrolled risk is closed.
The patterns we hit in this segment, this service, again and again.
Once paired, programmer can change pulse width / amplitude without re-authenticating. Stolen-programmer scenario is not modeled in the threat file.
Reverse-engineered companion app contained a single HMAC key used to sign implant commands. Compromise of one app = forged commands to any device of the model.
Internal sensing path between sense electrodes and stim controller has no integrity check. Bench fault-injection on the sense ADC drives unintended stimulation.
Authenticated clinician account can list devices outside their assigned clinic via predictable enumeration on the registry endpoint.
Recalls, CISA ICS-MA advisories, and disclosed research that shape what reviewers ask about in this segment - and what our scope is built to cover.
"Blue Goat's niche expertise in FDA-facing cybersecurity made all the difference. Their reports were built with the FDA's expectations in mind; it gave us confidence that we were submitting exactly what reviewers want to see."
The same deliverables the parent Medical Device Penetration Testing service ships with - tuned to your neurotech / bci architecture.
Reviewer-format documents ready to drop straight into the cybersecurity attachments of your submission - no reformatting on your side.
The NeuroTech / BCI baseline, plus the call-outs that matter for medical device penetration testing in this segment.
Cyber findings on stim parameters are essential-performance impacts. Risk-control treatment must reflect that, not be relegated to annex IT considerations.
Implant lifetimes (5-15 years) make the postmarket plan part of the premarket package. We test what's deployed AND what the update path looks like.
We scope tightly on purpose. These items are either out-of-scope by design or belong in a separate engagement - we'll tell you up front, not after kickoff.
The questions buyers in this segment actually ask before scoping a medical device penetration testing engagement.
A practical, ungated buyer's guide for medical device manufacturers evaluating cybersecurity partners, what goes wrong, why it costs you, and what to demand from your next engagement. Aligned to the FDA February 2026 premarket guidance.
The most common high- and critical-severity findings we surface in medical device penetration tests, what each one looks like in the field, and how to fix it before your FDA submission.
A practical, ungated guide to the threat modeling gaps that trigger FDA cybersecurity questions in 510(k), De Novo, and PMA submissions - and exactly how to close them before reviewers find them.
Medical device cybersecurity at each study stage: rodent, large animal, primate, and human trials, and what the FDA expects before your IDE and marketing submission.
What a medical device security advisor does after FDA clearance: keeping the threat model and SBOM current, rating vulnerabilities, and answering hospitals.
Threat modeling AI-enabled medical devices: how to add the model, training pipeline, and updates to your threat model, with a worked example of a fictional AI dosing advisor.
Teams in this segment commonly bundle these alongside medical device penetration testing.
A 30-minute call with a senior engineer who has done this in neurotech / bci before - not a sales rep.
